IQV Iqvia (IQV) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Services-commercial physical & biological research · CIK 0001478242
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
543
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $12.9M priced
What the filings say about IQV
Insiders, 180 days
-$29.9M net sold
6 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2026-09-14
Planned sales (Form 144), 90 days
$2.4M
3 notices
Iqvia insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, IQVIA HOLDINGS INC. insiders sold a net $29.9M of stock across 49 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 24.5% of the 10,890 shares held after it.
- 1 other insider sold within 30 days.
- 543 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Berkshire James G. sold about $697.2K of IQV on Sep 2, 2026; 1 other insider sold within 30 days and 543 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 29, 2024.
- The trade is 41.3% of the 13,312 shares held after it.
- 5 other insiders sold within 30 days.
- 543 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks STAUB W RICHARD sold about $1.3M of IQV on Aug 3, 2026; 5 other insiders sold within 30 days and 543 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 137.6% of the 1,348 shares held after it.
- 4 other insiders sold within 30 days.
- 543 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Patel Bhavik sold about $436.4K of IQV on Jul 31, 2026; 4 other insiders sold within 30 days and 543 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Dec 18, 2025.
- The trade is 0.5% of the 987,682 shares held after it.
- 4 other insiders sold within 30 days.
- 543 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks BOUSBIB ARI sold about $1.1M of IQV on Jul 29, 2026; 4 other insiders sold within 30 days and 543 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Dec 18, 2025.
- The trade is 0.5% of the 983,098 shares held after it.
- 4 other insiders sold within 30 days.
- 543 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks BOUSBIB ARI sold about $1.1M of IQV on Jul 29, 2026; 4 other insiders sold within 30 days and 543 funds added in the latest 13F quarter.49 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$29.9M over 180 days
-$2.4M over 90 days
below 91% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
543 funds bought in last quarter
more than 98% of Pharma & Biotech
Revenue
+5.9% year over year
more than 54% of Pharma & Biotech
Margin
8.3% net margin
more than 80% of Pharma & Biotech
Buybacks
$552.0M repurchased, FY to 2026-03-31
more than 87% of Pharma & Biotech
Short interest
1.9% of the float short (float per yahoo 2026-10-27) · 2.4 days to cover · settled 2026-10-15
below 67% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch IQV
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+24.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IQV: institutional holders (13F)
13F holdings, latest reported quarter
14,549,693 sh
$2.8B
12,183,830 sh
$2.4B
10,905,053 sh
$2.1B
7,508,244 sh
$1.5B
7,501,993 sh
$1.4B
Congress trades in IQV
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-14 · disclosed 11 days later
$15,001 - $50,000
Sold 2026-09-08 · disclosed 17 days later
$1,001 - $15,000
Sold 2026-09-03 · disclosed 22 days later
$1,001 - $15,000
Sold 2026-03-16 · disclosed 18 days later
$50,001 - $100,000
Sold 2025-05-15 · disclosed 16 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
IQV planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JAMES G BERKSHIRE
Filed 2026-09-02
$697.2K
WALTER STAUB
Filed 2026-08-03
$1.3M
BHAVIK PATEL
Filed 2026-07-31
$436.4K
ARI BOUSBIB
Filed 2026-07-29
$26.1M
KERIANN CHEROFSKY
Filed 2026-07-29
$136.8K
IQV mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Oakmark Global Select Fund
$53.9M position · as of 2026-06-30
6.6%
Oakmark Select Fund
$503.4M position · as of 2026-06-30
6.1%
Artisan Select Equity Fund
$5.1M position · as of 2026-06-30
5.2%
Global X HealthTech ETF
$1.2M position · as of 2026-05-31
4.7%
Clarkston Fund
$1.4M position · as of 2026-06-30
4.7%
Dana Concentrated Dividend ETF
$2.1M position · as of 2026-05-31
4.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Ari Bousbib
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$28.1M
$36.1M
$8.9M
+26%
+87%
2024
$26.7M
$11.5M
$6.6M
+10%
+59%
2023
$29.2M
$42.3M
$4.5M
+29%
+48%
2022
$30.1M
$6.0M
$5.0M
+14%
+38%
2021
$28.6M
$88.4M
$4.4M
+57%
+36%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $29.9M sold by insiders over 180 days, 543 funds added last quarter, $2.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
IQV financials
Revenue growth
+5.9%
XBRL, annual
Net margin
8.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$16.6B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM IQV
| FY Dec 2025 | $16.3B |
| FY Dec 2024 | $15.4B |
| FY Dec 2023 | $15.0B |
| FY Dec 2022 | $14.4B |
| FY Dec 2021 | $13.9B |
| Mar 2026 | $4.2B |
| Dec 2025 | $4.4B |
| Sep 2025 | $4.1B |
| Jun 2025 | $4.0B |
| Mar 2025 | $3.8B |
| Dec 2024 | $4.0B |
| Sep 2024 | $3.9B |
| Jun 2024 | $3.8B |
At each fiscal year end
Single quarter
Net margin, TTM
+8.3%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM IQV
| FY Dec 2025 | +8.3% |
| FY Dec 2024 | +8.9% |
| FY Dec 2023 | +9.1% |
| FY Dec 2022 | +7.6% |
| FY Dec 2021 | +7.0% |
| Mar 2026 | +6.6% |
| Dec 2025 | +11.8% |
| Sep 2025 | +8.1% |
| Jun 2025 | +6.6% |
| Mar 2025 | +6.5% |
| Dec 2024 | +11.0% |
| Sep 2024 | +7.3% |
| Jun 2024 | +9.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$2.1B
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM IQV
| FY Dec 2025 | $2.1B |
| FY Dec 2024 | $2.1B |
| FY Dec 2023 | $1.5B |
| FY Dec 2022 | $1.6B |
| FY Dec 2021 | $2.3B |
| Mar 2026 | $491.0M |
| Dec 2025 | $561.0M |
| Sep 2025 | $772.0M |
| Jun 2025 | $292.0M |
| Mar 2025 | $426.0M |
| Dec 2024 | $721.0M |
| Sep 2024 | $571.0M |
| Jun 2024 | $445.0M |
At each fiscal year end
Single quarter
Debt to equity
2.55x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-03-31
Debt to equity IQV
| FY Dec 2025 | 2.42x |
| FY Dec 2024 | 2.30x |
| FY Dec 2023 | 2.24x |
| FY Dec 2022 | 2.21x |
| FY Dec 2021 | 2.01x |
| Mar 2026 | 2.55x |
| Dec 2025 | 2.42x |
| Sep 2025 | 2.43x |
| Jun 2025 | 2.68x |
| Mar 2025 | 2.40x |
| Dec 2024 | 2.30x |
| Sep 2024 | 1.94x |
| Jun 2024 | 1.97x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.17x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Cash flow to debt IQV
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | 0.19x |
| FY Dec 2023 | 0.16x |
| FY Dec 2022 | 0.18x |
| FY Dec 2021 | 0.24x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.19x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.19x |
| Dec 2024 | 0.19x |
| Sep 2024 | 0.19x |
| Jun 2024 | 0.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+22.7%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity IQV
| FY Dec 2025 | +21.6% |
| FY Dec 2024 | +22.5% |
| FY Dec 2023 | +22.9% |
| FY Dec 2022 | +18.5% |
| FY Dec 2021 | +16.0% |
| Mar 2026 | +22.7% |
| Dec 2025 | +21.6% |
| Sep 2025 | +19.5% |
| Jun 2025 | +19.8% |
| Mar 2025 | +21.7% |
| Dec 2024 | +22.5% |
| Sep 2024 | +22.0% |
| Jun 2024 | +22.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.9%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets IQV
| FY Dec 2025 | +4.8% |
| FY Dec 2024 | +5.1% |
| FY Dec 2023 | +5.2% |
| FY Dec 2022 | +4.4% |
| FY Dec 2021 | +3.9% |
| Mar 2026 | +4.9% |
| Dec 2025 | +4.8% |
| Sep 2025 | +4.6% |
| Jun 2025 | +4.5% |
| Mar 2025 | +5.0% |
| Dec 2024 | +5.1% |
| Sep 2024 | +5.3% |
| Jun 2024 | +5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+9.2%
operating income after a 15.7% effective tax rate, over long-term 2026-03-31 plus current 2026-03-31 plus average of 2025-03-31 and 2026-03-31 minus cash
Return on invested capital IQV
| FY Dec 2025 | +9.1% |
| FY Dec 2024 | +9.7% |
| FY Dec 2023 | +10.0% |
| FY Dec 2022 | +8.4% |
| FY Dec 2021 | +7.2% |
| Mar 2026 | +9.2% |
| Dec 2025 | +9.1% |
| Sep 2025 | +8.9% |
| Jun 2025 | +8.8% |
| Mar 2025 | +9.4% |
| Dec 2024 | +9.7% |
| Sep 2024 | +10.6% |
| Jun 2024 | +10.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+10.6%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed IQV
| FY Dec 2025 | +10.5% |
| FY Dec 2024 | +11.0% |
| FY Dec 2023 | +9.9% |
| FY Dec 2022 | +9.2% |
| FY Dec 2021 | +7.1% |
| Mar 2026 | +10.6% |
| Dec 2025 | +10.5% |
| Sep 2025 | +10.8% |
| Jun 2025 | +10.7% |
| Mar 2025 | +10.9% |
| Dec 2024 | +11.0% |
| Sep 2024 | +10.5% |
| Jun 2024 | +10.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
33.95x
close 2026-10-26 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing IQV
| FY Dec 2025 | 28.71x |
| FY Dec 2024 | 26.24x |
| FY Dec 2023 | 31.78x |
| FY Dec 2022 | 35.88x |
| FY Dec 2021 | 56.88x |
| Mar 2026 | 21.16x |
| Dec 2025 | 28.71x |
| Sep 2025 | 26.09x |
| Jun 2025 | 22.84x |
| Mar 2025 | 24.05x |
| Dec 2024 | 26.24x |
| Sep 2024 | 31.14x |
| Jun 2024 | 27.50x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$59.5B
market value at close 2026-10-26 on 2026-04-30 shares, plus long-term 2026-03-31 plus current 2026-03-31, minus cash 2026-03-31
Enterprise value IQV
| FY Dec 2025 | $52.1B |
| FY Dec 2024 | $47.9B |
| FY Dec 2023 | $54.5B |
| FY Dec 2022 | $49.6B |
| FY Dec 2021 | $64.7B |
| Mar 2026 | $42.8B |
| Dec 2025 | $52.1B |
| Sep 2025 | $45.4B |
| Jun 2025 | $40.7B |
| Mar 2025 | $43.6B |
| Dec 2024 | $47.9B |
| Sep 2024 | $55.1B |
| Jun 2024 | $50.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield IQV
| FY Dec 2025 | +5.3% |
| FY Dec 2024 | +5.9% |
| FY Dec 2023 | +3.6% |
| FY Dec 2022 | +4.2% |
| FY Dec 2021 | +4.3% |
| Mar 2026 | +7.3% |
| Dec 2025 | +5.3% |
| Sep 2025 | +6.8% |
| Jun 2025 | +7.4% |
| Mar 2025 | +7.0% |
| Dec 2024 | +5.9% |
| Sep 2024 | +4.5% |
| Jun 2024 | +4.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
3.41x
P/E over trailing EPS growth of 10%: four quarters to 2026-03-31 against the four to 2025-03-31
PEG, trailing IQV
| FY Dec 2025 | 5.97x |
| FY Dec 2024 | 9.10x |
| FY Dec 2023 | 1.16x |
| FY Dec 2022 | 2.37x |
| FY Dec 2021 | 0.23x |
| Mar 2026 | 2.12x |
| Dec 2025 | 5.97x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 87.91x |
| Dec 2024 | 9.10x |
| Sep 2024 | 1.12x |
| Jun 2024 | 0.85x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $16.3B | $15.4B | $15.0B | $14.4B |
| Operating income | $2.2B | $2.2B | $2.0B | $1.8B |
| Net income | $1.4B | $1.4B | $1.4B | $1.1B |
| EPS (diluted) | 7.84 | 7.49 | 7.29 | 5.72 |
| Operating cash flow | $2.7B | $2.7B | $2.1B | $2.3B |
| Cash | $2.0B | $1.7B | $1.4B | $1.2B |
| Long-term debt | $13.9B | $12.8B | $13.0B | $12.6B |
| Buybacks | $1.2B | $1.4B | $992.0M | $1.2B |
SEC XBRL, fiscal years, as known on 2026-10-28
IQV Stock Sonar score 6/7 axes
Find similar shapesCompareIQV ranks highest on profitability (75th percentile) and risk and compliance (67th), and lowest on insider conviction (4th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
IQV filings, in plain words
Are Iqvia insiders buying or selling IQV?
In the 180 days to 2026-10-28, Iqvia insiders were net sellers, a net $29.9M across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded IQV?
Yes. In the year to 2026-10-28, 0 House members disclosed buying IQV and 1 House member disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-14.
Are there planned insider sales of IQV?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.4M of stock; the latest, by JAMES G BERKSHIRE, was filed 2026-09-02.
Read the full summary
In the 180 days to 2026-10-28, Iqvia insiders were net sellers of IQV, a net $29.9M across purchases and sales reported on Form 4 by 6 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 0 members of Congress disclosed buying IQV and 1 member disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-14. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
